Integration of Molecular Data in the Prognostic Stratification and Management of Endometrial Carcinoma
-
Published:2022-12-18
Issue:12
Volume:12
Page:2083
-
ISSN:2075-4426
-
Container-title:Journal of Personalized Medicine
-
language:en
-
Short-container-title:JPM
Author:
Raffone AntonioORCID, Travaglino Antonio, Raimondo Diego, Casadio Paolo, Seracchioli Renato, Zannoni GianORCID, Mollo Antonio
Abstract
In the last years, the TCGA-based molecular classifier have been progressively integrated in the management of endometrial carcinoma. While molecular assays are increasingly available across pathology laboratories, the additional costs will expectedly be compensated by a reduction in overtreatments and a prevention of recurrences. The additional time might be shortened by assessing molecular markers on biopsy specimens. Retrospective data suggest that the molecular classifier will have a major impact of on the risk stratification, with many patients having their risk class down- or upstaged based on POLE mutations or p53 abnormalities, respectively. However, there are still several issues to be resolved, such as the prognostic value of the TCGA classifier in each FIGO stage, or the type of adjuvant treatment most suitable for each molecular group. Other issues regard the prognostic stratification of the mismatch repair-deficient and “no specific molecular profile” groups, which currently follows the same criteria; however, the former seems to be prognostically consistent regardless of FIGO grade and histotype, whereas the latter appears highly heterogeneous. Numerous clinical, histological, immunohistochemical and molecular markers have been proposed to refine the TCGA classification, but their prognostic value is still undefined. Hopefully, prospective data collected in the next years will help resolving these issues.
Subject
Medicine (miscellaneous)
Reference30 articles.
1. Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67–73. 2. Santoro, A., Angelico, G., Travaglino, A., Inzani, F., Arciuolo, D., Valente, M., D’Alessandris, N., Scaglione, G., Fiorentino, V., and Raffone, A. (2021). New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers, 13. 3. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series;Kommoss;Ann. Oncol.,2018 4. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts;Stelloo;Clin. Cancer Res.,2016 5. Arciuolo, D., Travaglino, A., Raffone, A., Raimondo, D., Santoro, A., Russo, D., Varricchio, S., Casadio, P., Inzani, F., and Seracchioli, R. (2022). TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. Int. J. Mol. Sci., 23.
|
|